Long-term safety of efgartigimod injection for myositis
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This study tests the long-term safety and effectiveness of a subcutaneous (under-the-skin) version of efgartigimod for adults with active idiopathic inflammatory myopathy. It is for people who have already completed an earlier study of this medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the earlier study of efgartigimod (ARGX-113-2007).
- You must be able to give informed consent and follow the study rules.
- If you are a woman of childbearing age, you must agree to use birth control and have a negative pregnancy test before starting the medicine.
- You cannot have any planned major surgery or a new medical condition that could affect the study results.
- You cannot have a known allergy to the study drug or its ingredients.
- You cannot have developed a new or returning cancer (except some skin cancers) since joining the earlier study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
This trial tests a medicine called efgartigimod to treat autoimmune encephalitis (AIE)—a rare condition where the immune system attacks the brain. The study enrolls children 12+ and adults to see if this drug can reduce symptoms and help recovery.
This trial checks the long-term safety of efgartigimod given through an IV and as a quick under-the-skin injection in children with generalized myasthenia gravis (gMG). It may help your care team understand how safely this treatment can be used over time for kids who already took related study treatments.
This study tests an investigational drug called efgartigimod for children and teens with generalized myasthenia gravis. It may help those who haven't responded well enough to standard treatments.
This study tests a new treatment called efgartigimod for people who have been recently diagnosed with generalized myasthenia gravis (gMG). It aims to see if this medicine can help manage symptoms like muscle weakness.
Hear when a new Myositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.